




NPCA

National Prostate
Cancer Audit

NPCA, Clinical Effectiveness Unit
Royal College of Surgeons of England
38-43 Lincoln's Inn Fields
London WC2A 3PE

 NPCA@rcseng.ac.uk
 [@National Prostate Cancer Audit \(NPCA\)](https://www.linkedin.com/company/national-prostate-cancer-audit-npca)
 [@npca-natcan.bsky.social](https://bsky.app/profile/npca-natcan.bsky.social)


NPCA Newsletter, July 2026

NPCA Quality Improvement Intervention - Metastatic Prostate Cancer: Receipt of Systemic Anti-Cancer Treatment (SACT) Intensification

NPCA launched its first [Quality Improvement \(QI\) Intervention](#) to help ensure men with metastatic hormone-sensitive prostate cancer receive systemic treatment intensification where appropriate. This follows findings from the [NPCA State of the Nation Report 2025](#), which showed considerable variation in treatment rates across Specialist Multidisciplinary Teams (sMDTs).

As part of the intervention, the NPCA introduced a formal [outlier process](#) and, in collaboration with BURST, hosted [a webinar](#) exploring the evidence base for systemic anti-cancer therapy in metastatic prostate cancer.

A new performance indicator, reported at sMDT level, was introduced to the [NPCA data dashboard](#) in January 2026 : Proportion of men with newly diagnosed hormone-sensitive metastatic disease receiving systemic treatment intensification. The performance indicator was updated in April and July 2026, covering the cohort up to March 2024.



Webinar Recap:
Improving Data Collection Quality and Completeness for SACT in Prostate Cancer

[View Recording Here](#)

NPCA QI Intervention

KEY TAKEAWAYS

- ✓ National SACT data reveal **variation in treatment intensification across age groups and NHS Trusts**.
- ✓ Seemingly small system configuration issues can create significant gaps or inaccuracies in national treatment data.
- ✓ Practical actions can meaningfully improve data completeness and quality, including **reviewing regimen-mapping, validating local configurations and strengthening coordination across sites**.
- ✓ Establishing a **culture of routine audit, performance review, and shared responsibility across clinical and digital teams** supports reliable, high-quality SACT data.
- ✓ Data completeness and quality is a **shared responsibility** across pharmacy, IT, oncologists, urology teams, and data managers.

Panel Discussion

19 March 2026

Improving Data Collection Quality and Completeness for Systemic Anti-Cancer Therapy (SACT) in Prostate Cancer

National Prostate Cancer Audit team

On 19 March 2026, NPCA hosted [a second webinar](#) focused on [improving the quality and completeness of Systemic Anti-Cancer Therapy \(SACT\) in prostate cancer](#). The session featured representatives from the Royal Marsden NHS Foundation Trust and the Lancashire and South Cumbria Cancer Alliance, who shared their local approaches and best practices.

Key takeaways include:

- National SACT data reveal variation in treatment intensification across age groups and NHS organisations.
- Small system configuration issues can lead to major gaps or inaccuracies in national treatment data.
- Practical ways to improve data completeness include fixing regimen mapping problems and improving coordination across sites.
- Establishing a culture of routine audit, performance review, and shared responsibility across clinical and digital teams supports reliable, high-quality SACT data.
- Ongoing audit and feedback will be used to monitor progress and support improvement over time.

State of the Nation 2026

The NPCA State of the Nation (SotN) Report will be published on **8 October 2026**, bringing new insights into prostate cancer care across England and Wales. Read our [previous SotN Report](#) from 2025.

July Data Dashboard

The July update of the [NPCA data dashboard](#) is live. The next quarterly update will be released on Thursday **8 October 2026**.

New CRG Members

We are pleased to welcome Prof. Giuseppe Banna and Dr. Hilary Glen to the [NPCA Clinical Reference Group](#). They will bring valuable insights from a medical oncology perspective to the National Prostate Cancer Audit.

Communication

The NPCA will be moving away from posting updates on X so please join us on [Bluesky](#) and [LinkedIn](#) to receive news from the audit. Please tell your colleagues about joining our mailing list for all NPCA related updates.



This email was sent to you by , part of the National Cancer Audit Collaborating Centre (NATCAN) based at the Royal College of Surgeons of England. To ensure continued receipt of our emails please add us to your address book or safe list.
In accordance with the General Data Protection Regulation (GDPR), NATCAN is committed to protecting your privacy. If you wish to know more please access our privacy policy. If you no longer wish to receive any messages please unsubscribe. © RCS 2026, Registered Charity No. 2128.